GH Research (NASDAQ:GHRS) Sees Strong Trading Volume – Here’s What Happened

Shares of GH Research PLC (NASDAQ:GHRS) saw strong trading volume on Wednesday . Approximately 469,567 shares traded hands during mid-day trading, an increase of 52% from the previous session’s volume of 308,722 shares.The stock last traded at $30.38 and had previously closed at $29.08.

GH Research News Roundup

Here are the key news stories impacting GH Research this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for GH Research across several periods, including FY2026 EPS to ($1.14) from ($1.21) and FY2027 EPS to ($1.62) from ($1.64). The firm also modestly improved estimates for the second, third and fourth quarters of 2027. These revisions indicate expectations for somewhat narrower losses and reinforce HC Wainwright’s Buy rating.
• Positive Sentiment: The analyst’s long-term estimates project improving results by FY2030, when the expected loss narrows to ($1.22) per share from projected losses of ($1.76) in FY2028 and ($2.11) in FY2029. While GH Research remains pre-profit, the trajectory may support bullish sentiment among investors focused on the company’s longer-term development prospects.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting date. This provides no evidence of meaningful short-covering activity or a short-squeeze catalyst behind the recent strength.
• Negative Sentiment: GH Research is still expected to post losses in every forecast period provided, including a consensus loss of ($1.33) per share for the current year. The company’s valuation and stock performance therefore remain highly dependent on future clinical and commercial progress rather than near-term earnings.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GHRS. Zacks Research lowered shares of GH Research from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. New Street Research set a $65.00 target price on shares of GH Research in a report on Monday. Citizens Jmp reduced their price target on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research report on Friday, May 15th. Cantor Fitzgerald lifted their price objective on GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Wells Fargo & Company assumed coverage on GH Research in a report on Monday, July 27th. They issued an “overweight” rating and a $44.00 price objective for the company. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.00.

GH Research Trading Up 2.1%

The company has a market cap of $2.04 billion, a price-to-earnings ratio of -29.68 and a beta of 1.29. The firm’s fifty day moving average price is $25.88 and its 200-day moving average price is $20.37.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. As a group, research analysts anticipate that GH Research PLC will post -1.33 EPS for the current year.

Hedge Funds Weigh In On GH Research

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC raised its holdings in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares during the period. North Star Investment Management Corp. acquired a new position in shares of GH Research in the first quarter valued at approximately $31,000. Royal Bank of Canada increased its position in shares of GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after acquiring an additional 780 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of GH Research during the fourth quarter worth $38,000. Finally, Osaic Holdings Inc. raised its holdings in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the period. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.